Company intelligence / Profile preview

Jinhua Shouxiangu Pharmaceutical

Ownership: Private
Employees: ~1143
Development stage: Other

Overview

Zhejiang Shouxiangu Pharmaceutical specializes in breeding, cultivating, processing, and selling high-value traditional Chinese medicinal materials such as Lingzhi (Ganoderma lucidum), Dendrobium officinale ("Tiepishihu"), and saffron. It leads industry standards for these botanicals/fungi and has developed ISO standards for their quality. Its core business centers around commercialized herbal/TCM health products rather than Western-style pharmaceuticals or clinical-stage drug development[1][2][3].

Modalities: Small molecule (plant-derived extracts)Biologic (fungal and plant-based products)Herbal medicine (Traditional Chinese Medicine formulations)
Industry: Food & Nutrition

Partnerships

Participated with regulatory authorities to set national/provincial standards for key botanicals [3]

Beyond the preview

Go deeper on Jinhua Shouxiangu Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jinhua Shouxiangu Pharmaceutical.

Explore the full profile